Golden Valley Development Inc (GVDI)

[Mick Dodge]

FORT LAUDERDALE, FL--(Marketwired - Jun 3, 2015) - Golden Valley Development, Inc. (OTC PINK: GVDI) (the "Company"), a developer and marketer of patented and patentable technologies, is pleased to announce a purchase order agreement and strategic partnership with Mel-Mont Medical, LLC, ("Mel-Mont") to commercialize XytoTest™ worldwide. (www.xytotest.com).

The cervical cancer diagnostic test market will reach $9 billion by 2020 with an annual growth rate (CAGR) of 6.1%, according to Transparency Market Research. Over half a million cases are detected every year. Over 275,000 women die every year from cervical cancer, of which 85% of these deaths are in developing countries.

"No woman should die from cervical cancer. The real tragedy of cervical cancer is that it is easily preventable if detected early enough," stated Liliana Montes, Mel-Mont Medical CEO. "What is exciting with XytoTest™ is that now women can self-sample and actually receive more accurate, detailed results, so they can either get early care or avoid the disease completely. We are very excited about the opportunity to partner with Golden Valley Development because of their unique desire to work with patented medical devices for large scale commercialization."